KRAS and non-small cell lung carcinoma: A meta‐analysis including 138 NSCLC patients with KRAS MT and 371 with KRAS wild‐type (WT) MTs reported that ICIs improved OS in the KRAS MT cohort compared with docetaxel (HR = 0.64 [95% CI, 0.43–0.96], p = 0.03), while the KRAS wild‐type cohort showed no difference.21